TABLE 4.
Effects of sPLA2 and cPLA2 inhibition on basal eicosanoid production from MΦWT and MΦTg
| Lipid | MΦWT (n = 4) (pmol lipid/1e+06) | MΦTg (n = 3) (pmol lipid/1e+06) | ||||
| DMSO | +sPLA2 Inhibitor | +cPLA2 Inhibitor | DMSO | +sPLA2 Inhibitor | +cPLA2 Inhibitor | |
| 6-Keto PGF1α | 5.555 ± 0.585 | 4.775 ± 0.599 | 5.425 ± 1.082 | 9.418 ± 2.493 | 9.742 ± 1.732a | 9.604 ± 3.708 |
| TXB2 | 4.619 ± 0.173 | 4.575 ± 0.190 | 4.696 ± 0.188 | 4.949 ± 0.108 | 4.892 ± 0.294 | 5.108 ± 0.593 |
| PGE2 | 2.343 ± 0.297 | 2.320 ± 0.406 | 3.944 ± 1.372 | 3.734 ± 1.053 | 5.347 ± 1.074a | 8.549 ± 5.762 |
| PGA2 | 1.674 ± 0.114 | 1.550 ± 0.074 | 1.858 ± 0.207 | 1.850 ± 0.176 | 2.010 ± 0.143a | 2.008 ± 0.322 |
| PGD2 | 0.395 ± 0.058 | 0.330 ± 0.046 | 0.419 ± 0.067 | 0.413 ± 0.027 | 0.507 ± 0.145 | 0.705 ± 0.137 |
| PGF2α | 0.638 ± 0.043 | 0.536 ± 0.022 | 0.579 ± 0.053 | 0.613 ± 0.021 | 0.649 ± 0.032a | 00.685 ± 0.069 |
| PGE1 | 0.332 ± 0.059 | 0.288 ± 0.037 | 0.633 ± 0.250 | 0.532 ± 0.105 | 0.648 ± 0.167 | 1.239 ± 0.864 |
| Resolvin D1 | 0.516 ± 0.012 | 0.509 ± 0.008 | 0.506 ± 0.012 | 0.520 ± 0.017 | 0.514 ± 0.009 | 0.495 ± 0.006 |
| LTE4 | 0.928 ± 0.107 | 0.959 ± 0.151 | 0.762 ± 0.072 | 12.560 ± 1.089 | 1.879 ± 0.285a | 1.411 ± 0.600 |
| (±)14,15-DHET | 0.671 ± 0.018 | 0.639 ± 0.017 | 0.626 ± 0.021 | 0.664 ± 0.100 | 0.643 ± 0.026 | 0.678 ± 0.021 |
| (±)11,12-DHET | 0.761 ± 0.017 | 0.725 ± 0.016 | 0.757 ± 0.047 | 0.745 ± 0.010 | 0.729 ± 0.012 | 0.788 ± 0.027 |
| (±)8,9-DHET | 0.717 ± 0.052 | 0.655 ± 0.015 | 0.692 ± 0.052 | 0.697 ± 0.048 | 0.713 ± 0.021 | 0.881 ± 0.102 |
| (±)14(15)-EET | 0.458 ± 0.028 | 0.403 ± 0.009 | 0.458 ± 0.024 | 0.479 ± 0.044 | 0.432 ± 0.026 | 0.468 ± 0.032 |
| (±)8(9)-EET | 0.044 ± 0.014 | 0.111 ± 0.059 | 0.123 ± 0.077 | 0.182 ± 0.067 | 0.132 ± 0.073 | 0.048 ± 0.007 |
| 20-HETE | 48.113 ± 0.951 | 47.770 ± 1.245 | 46.796 ± 1.049 | 54.631 ± 5.502 | 52.000 ± 3.387 | 51.376 ± 2.587 |
| 15-HETE | 8.658 ± 0.492 | 8.344 ± 0.194 | 9.514 ± 0.749 | 9.049 ± 0.390 | 8.850 ± 0.367 | 10.759 ± 1.188 |
| 12-HETE | 26.115 ± 3.799 | 24.261 ± 1.304 | 30.636 ± 1.518 | 30.433 ± 3.028 | 27.678 ± 0.959 | 40.769 ± 5.260 |
| 5-HETE | 15.490 ± 0.906 | 15.002 ± 0.897 | 16.287 ± 1.389 | 16.100 ± 2.337 | 15.301 ± 1.812 | 17.798 ± 1.123 |
| EPA | 110.120 ± 4.666 | 108.113 ± 5.052 | 108.650 ± 6.474 | 120.756 ± 4.953 | 116.367 ± 3.977 | 123.173 ± 3.299 |
| DHA | 541.748 ± 25.043 | 528.699 ± 24.293 | 531.345 ± 24.191 | 528.597 ± 16.190 | 535.621 ± 26.864 | 539.104 ± 25.425 |
| AA | 1,416.140 ± 136.869 | 1,346.699 ± 115.662 | 1,413.377 ± 126.250 | 1,431.009 ± 165.233 | 1,391.521 ± 170.268 | 1,547.321 ± 140.321 |
| DHGLA | 461.100 ± 37.288 | 438.201 ± 39.349 | 457.010 ± 33.448 | 472.864 ± 54.049 | 427.581 ± 46.155 | 486.472 ± 17.667 |
Media from MΦWT and MΦTg treated with vehicle, sPLA2 inhibitor (LY315920), or cPLA2 inhibitor (CAY 10502) only were processed for lipidomics analyses. The data are mean ± SEM.
a
Significantly different from WT-sPLA2 inhibitor, P < 0.05.